



Immunotherapy for Non-small Cell Lung Cancer

Guest Editors:

Prof. Dr. Ramon Andrade De Mello

1. Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK

2. Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK

3. Post-Graduation Program in Medicine, Nine of July University, (UNINOVE), São Paulo 01525-001, SP, Brazil

Prof. Nam P. Nguyen

Department of Radiation Oncology, Howard University College of Medicine, Washington, DC, USA

Message from the Guest Editors

Dear Colleagues,

Non-small cell lung cancer (NSCLC) is a disease with high mortality world-wide. However, treatment approaches have been improving in the last few decades. Several immune checkpoints inhibitors acquired an important role in the clinical practice either in the adjuvant or in metastatic setting. Thus, this Special Issue will focus in the basic, translational, and clinical research in the field of immunotherapy in order to understand the future trends in this field.

Prof. Dr. Ramon Andrade De Mello

Prof. Nam P. Nguyen

Guest Editors

Deadline for manuscript submissions:

closed (12 November 2021)





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)